Relationship of Blood Pressure to Retinal Vessel Diameter in Type 1 Diabetes Mellitus

OBJECTIVE To examine the relationship of blood pressure (BP) and use of angiotensin-receptor blocker or angiotensin-converting enzyme inhibitor to retinal vessel diameter in normotensive, normoalbuminuric persons with type 1 diabetes mellitus. METHODS In a randomized, controlled clinical trial, clin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Archives of ophthalmology (1960) 2010-02, Vol.128 (2), p.198-205
Hauptverfasser: Klein, Ronald, Myers, Chelsea E, Klein, Barbara E. K, Zinman, Bernard, Gardiner, Robert, Suissa, Samy, Sinaiko, Alan R, Donnelly, Sandra M, Goodyer, Paul, Strand, Trudy, Mauer, Michael
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:OBJECTIVE To examine the relationship of blood pressure (BP) and use of angiotensin-receptor blocker or angiotensin-converting enzyme inhibitor to retinal vessel diameter in normotensive, normoalbuminuric persons with type 1 diabetes mellitus. METHODS In a randomized, controlled clinical trial, clinic and 24-hour ambulatory BPs were measured in persons with type 1 diabetes mellitus and gradable fundus photographs both at baseline (n = 147) and at 5-year follow-up (n = 124). Retinal arteriole and venule diameters were measured by a computer-assisted technique. Individual arteriole and venule measurements were combined into summary indexes that reflect the average retinal arteriole (central retinal arteriole equivalent [CRAE]) and venule (central retinal venule equivalent [CRVE]) diameter of an eye, respectively. RESULTS While controlling for age, study site, glycosylated hemoglobin level, and ambulatory pulse rate, the daytime ambulatory systolic (−0.29-μm effect per 1 mm Hg; P = .02), daytime ambulatory diastolic (−0.44-μm effect per 1 mm Hg; P = .04), nighttime ambulatory systolic (−0.27-μm effect per 1 mm Hg; P = .03), and 24-hour ambulatory systolic (−0.31-μm effect per 1 mm Hg; P = .03) BPs were cross-sectionally associated with a smaller CRAE. While controlling for age, study site, glycosylated hemoglobin level, ambulatory pulse rate, and baseline CRAE, no BP measure was associated with a change in CRAE or CRVE during 5 years of follow-up. Treatment with losartan potassium or enalapril maleate was not associated with a statistically significant change in CRAE or CRVE. CONCLUSION Angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker therapy does not affect retinal arteriole or venule diameter in normotensive persons with type 1 diabetes mellitus. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00143949Arch Ophthalmol. 2010;128(2):198-205-->
ISSN:0003-9950
2168-6165
1538-3601
2168-6173
DOI:10.1001/archophthalmol.2009.391